Back to top

MBX: Leadership Transition, Pipeline Visibility Support Maintained Buy Rating and Unchanged $91 Price Target

Analyst Patrick Dolezal of LifeSci Capital maintained a Buy rating on MBX Biosciences, Inc., retaining the price target of $91.00. Patrick Dolezal ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE: